Effect of Pre-injection of Ranibizumab Followed by Pars-plana Vitrectomy in the Treatment of DR patients with NVG
Objective:To investigate the effect of pre-injection of Ranibizumab followed by pars-plana vitrectomy(PPV)in the Treatment of diabetic retinopathy(DR)patients with neovascular glaucoma(NVG).Method:Fifty DR patients with NVG who treated in Affiliated Central Hospital of Jiangnan University from June 2020 to June 2023 were selected as the study objects,and they were divided into the PPV-only group(short for the PPV group,24 cases with 24 eyes)and the pre-injection of Ranibizumab followed by PPV(short for the combination monoclonal antibody group,26 cases with 26 eyes)according to the method of table of random digit.The changes of ocular condition and serological indexes before treatment and 3 months after operation were compared between two groups,and the postoperative complications of two groups were observed.Result:At 3 months after operation,the ocular condition and serological indexes of two groups were improved compared with those before treatment,and the intraocular pressure,central macular thickness(CMT),vascular endothelial growth factor(VEGF)and insulin-like growth factor-1(IGF-1)levels in the combined monoclonal antibody group were lower than those in the PPV group,and the best corrected visual acuity(BCVA)was higher than that in the PPV group,the differences were statistically significant(P＜0.05).There was no significant difference in the incidence of postoperative complications between the combined monoclonal antibody group and the PPV group(P＞0.05).Conclusion:Pre-injection of Ranibizumab followed by PPV can effectively reduce intraocular pressure,eliminate macular edema,promote the recovery of patients'postoperative visual function,and reduce the levels of VEGF and IGF-1,with high safety.
国家科技期刊平台
NSTL
万方数据
